We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Liraglutide pharmacotherapy reduces body weight and improves glycaemic control in juvenile obese/hyperglycaemic male and female rats.
- Authors
Liberini, Claudia G.; Lhamo, Rinzin; Ghidewon, Misgana; Ling, Tyler; Juntereal, Nina; Chen, Jack; Cao, Anh; Stein, Lauren M.; Hayes, Matthew R.
- Abstract
Aims: To examine whether the glucagon‐like peptide‐1 receptor agonist liraglutide could be used in juvenile male and female rats as an anti‐obesity/diabetic pharmaceutical to prevent not only adolescent obesity/hyperglycaemia, but also early‐adult onset obesity. Material and Methods: Pregnant dams were fed either standard chow or a high‐fat, high‐sucrose diet (HFSD) from gestational day 2, throughout pregnancy and lactation. Offspring were weaned onto the respective maternal diet. Juveniles received daily subcutaneous injection of liraglutide (50 μg/kg, from postnatal day [PND]30 to PND40 and 200 μg/kg from PND40 to PND60) or vehicle. Food intake, body weight and glycaemic levels were evaluated across the experimental period. Results: Chronic liraglutide administration in juveniles prevented body weight gain in males and retained a normoglycaemic profile in both male and female rats. Conclusion: These preclinical data suggest that maternal and early‐life consumption of an HFSD increases caloric intake, body weight gain and hyperglycaemia, a collective set of unwanted metabolic effects that appear to be treatable in juveniles with liraglutide pharmacotherapy intervention.
- Subjects
OBESITY; BODY weight; HIGH-carbohydrate diet; METABOLIC disorders; DRUG therapy
- Publication
Diabetes, Obesity & Metabolism, 2019, Vol 21, Issue 4, p866
- ISSN
1462-8902
- Publication type
Article
- DOI
10.1111/dom.13591